Loading data for INDP — first visit, this takes a few seconds.
Indaptus Therapeutics, Inc. (INDP)
NasdaqCM: INDP
· 即時價格 · USD
1.85
+0.63 (51.64%)
收盤價： Sep 09, 2026, 4:03 PM
股價、關鍵數字和最新消息，都在這一頁。
Indaptus Therapeutics, Inc.（INDP）股價、分析與資料
無可用資料
| 買價 | 1.38 |
| 市值 | 296M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -15.4M |
| 1.17 | |
| -3.56 | |
| n/a | |
| -1.6 | |
| P/B (ttm) | 26.11 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 2.27 |
| 成交量 | 8,288,745 |
| 20 日平均成交量 | 478,700 |
| 開盤價 | 1.29 |
| 前收盤價 | 1.22 |
| 當日區間 | 1.27 - 1.93 |
| 52 週範圍 | 0.92 - 8.57 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 INDP
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as f...
完整的公司簡介財報驚奇
Indaptus Therapeutics 已於 Mar 17, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -9.19 低於預期 -4.83, 年增 13.63% 成長.